Ori Barzilai1, Mary-Kate Amato1, Lily McLaughlin1, Anne S Reiner2, Shahiba Q Ogilvie1, Eric Lis3, Yoshiya Yamada4, Mark H Bilsky1,5, Ilya Laufer1,5. 1. Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center New York, New York, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center New York, New York, USA. 3. Department of Radiology, Memorial Sloan-Kettering Cancer Center New York, New York, USA. 4. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center New York, New York, USA. 5. Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA.
Abstract
BACKGROUND: Patient-reported outcomes (PRO) represent an important measure of cancer therapy effect. For patients with metastatic epidural spinal cord compression (MESCC), hybrid therapy using separation surgery and stereotactic radiosurgery preserves neurologic function and provides tumor control. There is currently a paucity of data reporting PRO after such combined modality therapy for MESCC. Delineation of hybrid surgery-radiosurgery therapy effect on PRO validates the hybrid approach as an effective therapy resulting in meaningful symptom relief. PATIENTS AND METHODS: Brief Pain Inventory (BPI) and MD Anderson Symptom Inventory-Spine Tumor (MDASI-SP), PROs validated in the cancer population, were prospectively collected. Patients with MESCC who underwent separation surgery followed by stereotactic radiosurgery were included. Separation surgery included a posterolateral approach without extensive cytoreductive tumor excision. A median postoperative radiosurgery dose of 2700 cGy was delivered. The change in PRO 3 months after the hybrid therapy represented the primary study outcome. Preoperative and postoperative evaluations were analyzed using the Wilcoxon signed-rank test for matched pairs. RESULTS: One hundred eleven patients were included. Hybrid therapy resulted in a significant reduction in the BPI items "worst" and "right now" pain (P < .0001), and in all BPI constructs (severity, interference with daily activities, and pain experience, P < .001). The MDASI-SP demonstrated reduction in spine-specific pain severity and interference with general activity (P < .001), along with decreased symptom interference (P < .001). CONCLUSIONS: Validated PRO instruments showed that in patients with MESCC, hybrid therapy with separation surgery and radiosurgery results in a significant decrease in pain severity and symptom interference. These prospective data confirm the benefit of hybrid therapy for treatment of MESCC and should facilitate referral of patients with MESCC for surgical evaluation.
BACKGROUND: Patient-reported outcomes (PRO) represent an important measure of cancer therapy effect. For patients with metastatic epidural spinal cord compression (MESCC), hybrid therapy using separation surgery and stereotactic radiosurgery preserves neurologic function and provides tumor control. There is currently a paucity of data reporting PRO after such combined modality therapy for MESCC. Delineation of hybrid surgery-radiosurgery therapy effect on PRO validates the hybrid approach as an effective therapy resulting in meaningful symptom relief. PATIENTS AND METHODS: Brief Pain Inventory (BPI) and MD Anderson Symptom Inventory-Spine Tumor (MDASI-SP), PROs validated in the cancer population, were prospectively collected. Patients with MESCC who underwent separation surgery followed by stereotactic radiosurgery were included. Separation surgery included a posterolateral approach without extensive cytoreductive tumor excision. A median postoperative radiosurgery dose of 2700 cGy was delivered. The change in PRO 3 months after the hybrid therapy represented the primary study outcome. Preoperative and postoperative evaluations were analyzed using the Wilcoxon signed-rank test for matched pairs. RESULTS: One hundred eleven patients were included. Hybrid therapy resulted in a significant reduction in the BPI items "worst" and "right now" pain (P < .0001), and in all BPI constructs (severity, interference with daily activities, and pain experience, P < .001). The MDASI-SP demonstrated reduction in spine-specific pain severity and interference with general activity (P < .001), along with decreased symptom interference (P < .001). CONCLUSIONS: Validated PRO instruments showed that in patients with MESCC, hybrid therapy with separation surgery and radiosurgery results in a significant decrease in pain severity and symptom interference. These prospective data confirm the benefit of hybrid therapy for treatment of MESCC and should facilitate referral of patients with MESCC for surgical evaluation.
Authors: Mark H Bilsky; Ilya Laufer; Daryl R Fourney; Michael Groff; Meic H Schmidt; Peter Paul Varga; Frank D Vrionis; Yoshiya Yamada; Peter C Gerszten; Timothy R Kuklo Journal: J Neurosurg Spine Date: 2010-09
Authors: John DeVine; Daniel C Norvell; Erika Ecker; Daryl R Fourney; Alex Vaccaro; Jeff Wang; Gunnar Andersson Journal: Spine (Phila Pa 1976) Date: 2011-10-01 Impact factor: 3.468
Authors: Terri S Armstrong; Ibrahima Gning; Tito R Mendoza; Elizabeth Vera-Bolanos; Mark R Gilbert; Laurence D Rhines; Jeffrey S Weinberg; Gisela Sanchez-Williams; Victor Levin; Allen W Burton; Charles Cleeland Journal: J Neurosurg Spine Date: 2010-04
Authors: Zachary D Epstein-Peterson; Adam Sullivan; Monica Krishnan; Julie T Chen; Marco Ferrone; John Ready; Elizabeth H Baldini; Tracy Balboni Journal: Pract Radiat Oncol Date: 2015-04-06
Authors: Thomas M Atkinson; Barry D Rosenfeld; Laura Sit; Tito R Mendoza; Mike Fruscione; Dawn Lavene; Mary Shaw; Yuelin Li; Jennifer Hay; Charles S Cleeland; Howard I Scher; William S Breitbart; Ethan Basch Journal: J Pain Symptom Manage Date: 2010-12-04 Impact factor: 3.612
Authors: Alexis Falicov; Charles G Fisher; Joe Sparkes; Michael C Boyd; Peter C Wing; Marcel F Dvorak Journal: Spine (Phila Pa 1976) Date: 2006-11-15 Impact factor: 3.468
Authors: Nicolas Dea; Raphaële Charest-Morin; Daniel M Sciubba; Justin E Bird; Alexander C Disch; Addisu Mesfin; Áron Lazáry; Charles G Fisher; Christopher Ames Journal: Spine (Phila Pa 1976) Date: 2016-10-15 Impact factor: 3.468
Authors: Ori Barzilai; Lily McLaughlin; Eric Lis; Anne S Reiner; Mark H Bilsky; Ilya Laufer Journal: Oper Neurosurg (Hagerstown) Date: 2019-05-01 Impact factor: 2.703
Authors: Ori Barzilai; Lily McLaughlin; Mary-Kate Amato; Anne S Reiner; Shahiba Q Ogilvie; Eric Lis; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer Journal: Spine J Date: 2017-11-06 Impact factor: 4.166
Authors: Ibrahim Hussain; Jacob L Goldberg; Joseph A Carnevale; Samuel Z Hanz; Anne S Reiner; Adam Schmitt; Daniel S Higginson; Yoshiya Yamada; Ilya Laufer; Mark H Bilsky; Ori Barzilai Journal: Neurosurgery Date: 2022-02-01 Impact factor: 5.315
Authors: F Cofano; G Di Perna; A Alberti; B M Baldassarre; M Ajello; N Marengo; F Tartara; F Zenga; D Garbossa Journal: J Bone Oncol Date: 2020-11-10 Impact factor: 4.072
Authors: Giuseppe Di Perna; Fabio Cofano; Cristina Mantovani; Serena Badellino; Nicola Marengo; Marco Ajello; Ludovico Maria Comite; Giuseppe Palmieri; Fulvio Tartara; Francesco Zenga; Umberto Ricardi; Diego Garbossa Journal: J Bone Oncol Date: 2020-09-26 Impact factor: 4.072
Authors: Robert J Rothrock; Ori Barzilai; Anne S Reiner; Eric Lis; Adam M Schmitt; Daniel S Higginson; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer Journal: Neurosurgery Date: 2021-01-13 Impact factor: 4.654
Authors: William C Newman; John Berry-Candelario; Jemma Villavieja; Anne S Reiner; Mark H Bilsky; Ilya Laufer; Ori Barzilai Journal: Neurosurgery Date: 2021-04-15 Impact factor: 4.654
Authors: Ori Barzilai; Stefano Boriani; Charles G Fisher; Arjun Sahgal; Jorrit Jan Verlaan; Ziya L Gokaslan; Aron Lazary; Chetan Bettegowda; Laurence D Rhines; Ilya Laufer Journal: Global Spine J Date: 2019-05-08